Syngulon

Executive Summary

Syngulon is a Belgian synthetic biology startup (founded 2013) that leverages naturally occurring antimicrobial peptides called bacteriocins to address key challenges in microbial fermentation. The company's core technology enables antibiotic-free genetic selection, precision contamination control, and yield improvement in industrial bioprocesses. By replacing conventional antibiotics with bacteriocins, Syngulon aims to reduce antimicrobial resistance risks and improve process efficiency. The platform has potential applications across biomanufacturing, food production, and therapeutics. While still privately held with limited public financial details, Syngulon's focus on sustainable, antibiotic-free solutions positions it well in the growing synthetic biology and microbiome markets. The company's technology is validated through research collaborations and patents, but commercial traction remains nascent. We assign a conviction score of 65, reflecting the innovative approach yet early-stage uncertainty.

Upcoming Catalysts (preview)

• Q4 2026Partnership with a major industrial biotech or fermentation company for technology validation40% success
• Q2 2027Closing of a Series A or significant grant to scale development35% success
• Q1 2028Launch of a first commercial product for contamination control in fermentation30% success